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Abstract
Background: Peritoneal tumor dissemination arising from colorectal cancer, appendiceal cancer,
gastric cancer, gynecologic malignancies or peritoneal mesothelioma is a common sign of advanced
tumor stage or disease recurrence and mostly associated with poor prognosis.
Methods and results: In the present review article preoperative workup, surgical technique,
postoperative morbidity and mortality rates, oncological outcome and quality of life after CRS and
HIPEC are reported regarding the different tumor entities.
Conclusion:  Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy
(HIPEC) provide a promising combined treatment strategy for selected patients with peritoneal
carcinomatosis that can improve patient survival and quality of life. The extent of intraperitoneal
tumor dissemination and the completeness of cytoreduction are the leading predictors of
postoperative patient outcome. Thus, consistent preoperative diagnostics and patient selection are
crucial to obtain a complete macroscopic cytoreduction (CCR-0/1).
Background
Peritoneal carcinomatosis is a common sign of advanced
tumor stage, disease progression or recurrence in numer-
ous tumor entities of gastrointestinal or gynecological ori-
gin. Moreover, there are primary peritoneal malignancies
such as malignant peritoneal mesothelioma or primary
peritoneal carcinoma. In general, the diagnosis of perito-
neal tumor manifestation is associated with poor progno-
sis. In the European multicenter EVOCAPE I study the
median survival rates were 5.2 months for advanced
colorectal cancer (CRC, n = 118) and 3.1 months for
advanced gastric cancer (GC, n = 125), respectively[1].
The median survival rate in patients with stage IV ovarian
cancer (OC) range from 12 to 23 months [2-4]. For diffuse
malignant peritoneal mesothelioma (DMPM) median
survival rates of less than one year are reported in most
existing studies [5-7]. However, in a Phase II trial with sys-
temic application of permetrexed and gemcitabine the
median survival rate was 26.8 months in patients with
malignant peritoneal mesothelioma [8]. The treatment of
choice for patients with peritoneal surface malignancies is
palliative systemic chemotherapy. In the past, surgery was
performed in palliative intention for prevention or ther-
apy of tumor-related complications such as gastrointesti-
nal obstruction, bleeding or tumor perforation [9]. Solely,
in ovarian cancer cytoreductive surgery was already estab-
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lished as an inherent part of the standard treatment regi-
men [10]. In the early 1990's Sugarbaker et al. introduced
cytoreductive surgery (CRS) and hyperthermic intraperi-
toneal chemotherapy (HIPEC) as a new innovative thera-
peutic option for selected patients with peritoneal
carcinomatosis [11,12]. Over the years peritoneal carcino-
matosis treatment centers were established in the United
States, Europe and Japan. Feasibility, efficacy and safety of
CRS and HIPEC have been proved in numerous clinical
trials. In the present review article patient selection, treat-
ment strategy, mortality and morbidity rates and oncolog-
ical outcome is reported regarding the different tumor
entities.
Cytoreductive surgery
CRS consists of numerous surgical procedures depending
on the extent of peritoneal tumor manifestation. In
appendiceal malignancies, the omental cake, a dissemi-
nated tumor infiltration of the greater omentum, repre-
sents the most affected abdominal area (Fig. 1). Surgery
may include parietal and visceral peritonectomy, greater
omentectomy, splenectomy, cholecystectomy, resection
of liver capsule, small bowel resection, colonic and rectal
resection, (subtotal) gastrectomy, lesser omentectomy,
pancreatic resection, hysterectomy, ovariectomy and
urine bladder resection. In patients with mucinous
tumors and infiltration of the umbilicus, an omphalec-
tomy is necessary. Extraperitoneal dissection may enable
the anterior parietal peritonectomy and avoid a tumor
contamination of the abdominal wall (Fig. 2). The extent
of intraperitoneal tumor manifestation is determined
using the peritoneal cancer index (PCI), a combined
numerical score of lesion size (LS-0 to LS-3) and tumor
localization (region 0–12) [13,14]. The aim of CRS is to
obtain complete macroscopic cytoreduction (CCR-0/1) as
a precondition for the application of HIPEC. The residual
disease is classified intraoperatively using the complete-
ness of cytoreduction (CCR) score. CCR-0 indicates no
visible residual tumor and CCR-1 residual tumor nodules
≤ 2.5 mm. CCR-2 and CCR-3 indicate residual tumor nod-
ules between 2.5 mm and 2.5 cm and > 2.5 cm, respec-
tively [14].
Hyperthermic intraperitoneal chemotherapy
In case of complete macroscopic cytoreduction (CCR-0/1)
CRS is followed by hyperthermic intraperitoneal chemo-
therapy (HIPEC). The theoretical advantage of the intra-
peritoneal distribution of cytostatics is a high local
concentration of the used agents and reduced systemic
toxicity.  In vitro studies could show that hyperthermia
may potentiate the cytostatic effects. For example an
improved tissue penetration could be shown for cisplatin.
Moreover, hyperthermia leads to direct cytotoxic effects
such as protein denaturation, induction of apoptosis and
inhibition of angiogenesis [15].
For the performance of HIPEC one inflow and three out-
flow drainages are placed subphrenically and in the small
pelvis. The cytostatic agent is applied via the inflow drain-
age using a roller pump and heat exchanger in a closed
system that allows perfusate circulation (Fig. 3). The intra-
peritoneal temperature is monitored by two sensors
placed in the inflow catheter and in the Douglas pouch.
The intraperitoneal temperature should reach 41–42°C
leading to an inflow temperature of about 43°C.
Until today the cytostatic agents, combinations and con-
centrations used for HIPEC are not standardized for all
'Omental cake' in a patient with peritoneal carcinomatosis  arising from appendiceal cancer Figure 1
'Omental cake' in a patient with peritoneal carcino-
matosis arising from appendiceal cancer.
Omphalectomy in a patient with umbilical tumor infiltration Figure 2
Omphalectomy in a patient with umbilical tumor 
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peritoneal carcinomatosis centers worldwide. Thus,
numerous different protocols are used for the different
tumor entities. The perfusion times ranges from 30 to 120
minutes depending on the protocol and the drug used.
Moreover, numerous different drugs and drug combina-
tions are used (Table 1). HIPEC can be performed in open
or closed abdomen technique. One of the leading advan-
tages of the open technique is a better control of the intra-
peritoneal circulation and uniform distribution of the
cytostatic agents. An important disadvantage is the
increased risk of contamination compared to the closed
abdomen technique. Although a comparism of the exist-
ing studies is difficult there seem to be no significant dif-
ferences between the two techniques regarding morbidity
and mortality rates as well as patient survival [16].
Preoperative diagnostics and patient selection
Preoperative patient selection plays a pivotal role for the
success of CRS and HIPEC regarding clinical as well as
oncological patient outcome. Thus, preoperative diagnos-
tics including physical examination, laboratory parame-
Schematic diagram of HIPEC procedure Figure 3
Schematic diagram of HIPEC procedure.
Table 1: Selected studies with CRS and HIPEC in patients with peritoneal carcinomatosis of different origin.
Author, year n Tumor entity Cytostatic 
agent(s)
Morbidity Mortality Median survival Overall survival Survival
CCR-0/1
[%] [%] [months] [%] [%]
Verwaal, 
2003[25,41]
105 CRC MMC 35 8 22 28 (3-y) 45 (5-y)
Glehen, 2004[33] 506 CRC MMC/LOHP 23 4 19 39 (3-y) 47 (3-y)
Shen, 2004[34] 77 CRC MMC 30 12 16 25 (3-y) 44 (3-y)
Glehen, 2004[29] 49 GC MMC 27 4 10 8 (5-y) 29 (5-y)
Hall, 2004[45] 34 GC MMC 35 0 11 - 21 (5-y)
Yonemura, 
2005[30]
105 GC MMC/DDP 22 3 19 7 (5-y) 27 (5-y)
Feldmann, 2003[35] 49 DMPM DDP 25 0 92 59 (5-y) -
Deraco, 2006[36] 49 DMPM DDP/DXR
DDP/MMC
27 0 - 57 (5-y) -
Yan, 2007[27] 70 DMPM DDP/DXR 36 3 59 49 (5-y) -
Piso, 2004[37] 19 OC DDP; MITO 28 5 33 15 (5-y) 44 (5-y)
Cotte, 2007[38] 81 OC DDP 14 3 28 - -
Di Giorgio, 
2008[26]
47 OC DDP 21 4 30 17 (5-y) 26 (5-y)
CRC: colorectal cancer, GC: gastric cancer, PMP: pseudomyxoma peritonei, OC: ovarian cancer, DMPM: diffuse malignant peritoneal 
mesothelioma, MMC: mitomycin C, DDP: cisplatin, LOHP: oxaliplatin, DXR: doxorubicin, MITO: mitoxantroneWorld Journal of Surgical Oncology 2009, 7:5 http://www.wjso.com/content/7/1/5
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ters, tumor markers (CA19-9, CEA, CA125, CA72-4),
computed tomography of the chest, abdomen and pelvis
with intravenous and oral/rectal contrast and endoscopy
with or without endoluminal ultrasonography (colorectal
and gastric cancer) are indispensable (Table 2). In some
cases additional ultrasound, abdominal magnetic reso-
nance imaging (MRI) and/or PET-CT may be helpful
depending on the primary tumor and tumor dissemina-
tion [17]. However, Esquivel et al. have shown that preop-
erative CT-PCI does not correlate with the intraoperative
PCI. In 52 patients with peritoneal carcinomatosis of
colonic origin from 19 international centers the mean CT-
PCI was 8.6 vs. 13.2 (Esquivel, SSO 2008). In our experi-
ence a leading reason for incomplete macroscopic cytore-
duction is the intraoperative finding of disseminated
tumor spots in the small bowel region. Thus, staging
laparoscopy should be performed if necessary to deter-
mine tumor dissemination especially in patients with
peritoneal carcinomatosis from gastric cancer but not in
patients with DMPM because of the high risk of port side
metastasis [18,19]. Anyway, the tumor entity should be
taken into account. Whereas for example patients with
peritoneal carcinomatosis of colonic origin with a PCI ≤
20 qualify for CRS and HIPEC, the PCI in patients with
gastric cancer should be < 10 or ≤15 [20,21]. In patients
with pseudomyxoma peritonei arising from mucinous
neoplasms PCI > 20 is no absolute exclusion criteria. In
these patients tumor grading, extent of mesenteric inva-
sion, liver metastasis and age play an important role in
conjunction with PCI [22]. The Peritoneal Surface Malig-
nancy Group defined eight clinical and radiological varia-
bles that increase the probability of complete macroscopic
cytoreduction in patients with peritoneal carcinomatosis
of colonic origin: (1) ECOG performance status ≤ 2, (2)
no evidence of extra-abdominal disease, (3) up to three
small, resectable parenchymal hepatic metastases, (4) no
evidence of bilary obstruction, (5) no evidence of ureteral
obstruction, (6) no evidence of intestinal obstruction at
more than one site, (7) small bowel involvement: no evi-
dence of gross disease in the mesentery with several seg-
mental sites of partial obstruction and (8) small volume
disease in gastro-hepatic ligament [20,23]. In patients
with DMPM extra-abdominal and hepatic metastasis, his-
tology, nuclear grade and mitotic count are crucial prog-
nostic factors for preoperative patient selection and
oncological outcome [18]. Most experts exclude patients
with distant metastasis from primary and recurrent gastric
cancer [21]. The ovary consensus panel (OCP) found no
absolute contraindications for CRS and HIPEC in patients
with ovarian cancer regarding tumor dissemination or
metastasis. The access should be individually evaluated.
Nevertheless, heart failure and pulmonary compromise
preclude the combined treatment concept [24].
Morbidity and mortality
In the literature morbidity and mortality rates after CRS
and HIPEC range from 25% to 41% and from 0% to 8%,
respectively (Table 1) [25-38]. Morbidity can be divided
in surgery-related and chemotherapy-related complica-
tions. Common surgery-related complications are for
example postoperative ileus, anastomotic leakage, wound
infection, bleeding, thrombosis and lung embolism. The
different cytostatic agents used for HIPEC can lead to leu-
copenia, anemia, thrombopenia, heart, liver or renal tox-
icity and other side effects.
In a prospective study of 70 patients with DMPM Yan et
al. found primary colonic anastomosis, more than four
peritonectomy procedures (total anterior parietal peri-
tonectomy, greater omentectomy/splenectomy, sub-
phrenic peritonectomy, pelvic peritonectomy, lesser
omentectomy/cholecystectomy) and operating time
Table 2: Preoperative diagnostic workup.
Essential preoperative diagnostics
Clinical investigation
Laboratory testing incl. tumor markers
Computed tomography (CT) of the chest, abdomen and pelvis with oral, rectal and intravenous contrast
Tumor-specific essential diagnostics
CRC: complete colonoscopy
GC: gastroscopy
Useful additional diagnostics (case-dependent)
Ultrasonography
Magnetic resonance imaging (MRI)
Positron emission tomography (PET)/PET-CT
Diagnostic laparoscopy
CRC: colorectal cancer, GC: gastric cancerWorld Journal of Surgical Oncology 2009, 7:5 http://www.wjso.com/content/7/1/5
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greater than 7 hours to be associated with grade IV mor-
bidity [27]. The grade III and IV morbidity rate were 27%
and 14%, respectively. The perioperative mortality rate
was 3%. Hansson et al. analyzed 123 patients treated with
CRS and HIPEC for peritoneal carcinomatosis [39]. The
grade III/IV morbidity rate and the treatment-related mor-
tality rate were 41% and 4%, respectively. Bowel morbid-
ity was associated with electroevaporation or excision of
tumor nodes on the small bowel surface. In conclusion,
morbitity rates after CRS and HIPEC are relatively high
but comparable to other major gastrointestinal surgery.
However, in the existing studies the assessment of mor-
bidity is not standardized and therefore often not compa-
rable. Thus, following the consensus statement from
Milan in further studies the classification system CTCAE
version 3.0 should be used. Morbidity is classified in
minor complications (grade 0 to 2) and major complica-
tions (grade 3 to 5). Moreover, the classification system
includes 28 categories leading to an efficient assessment
of morbidity [40].
Survival rates
Several studies have shown that CRS and HIPEC as an
integrative part of an interdisciplinary cancer treatment
concept may improve survival of patients with peritoneal
dissemination of different tumor entities such as colorec-
tal cancer (CRC), gastric cancer (GC), ovarian cancer (OC)
and diffuse malignant peritoneal mesothelioma (DMPM)
(Table 1).
There are two prospective randomized controlled trials
(RCT), one non-randomized comparative study and
numerous observational studies regarding clinical and
oncologiocal outcome of patients with peritoneal carcino-
matosis arising from CRC. Verwaal et al. reported a dis-
ease-specific survival of 22.2 months after additional CRS
and HIPEC vs. 12.6 months after standard systemic treat-
ment with 5-FU and leucovorin [25,41]. In patients with
complete macroscopic cytoreduction (CCR-0/1) median
survival was 48 months and 5-year survival rate was 45%,
respectively. The second RCT was closed after inclusion of
only 35 patients during a 4 year accrual period. The 2-year
survival rates were 60% in both arms [42]. In the compar-
ative study published by Mahteme et al. the median sur-
vival in the HIPEC group was 32 months vs. 14 months in
the control group. 5-year survival rates were 28% and 5%
respectively [43]. In the observational studies the overall
median survival ranged from 15 to 32 months and from
28 to 60 months after complete macroscopic cytoreduc-
tion (CCR0-1), respectively [9].
The prognosis of patients with peritoneal tumor dissemi-
nation from GC is poor but could be significantly
improved by CRS and HIPEC in selected patients. Six
observational studies including between 17 and 154
patients showed median survival rates ranging from 10 to
19 months [28-31,44,45]. The 5-year survival rates after
complete macroscopic cytoreduction (CCR-0/1) were
21%, 27%, 29%, 31% and 32%, respectively. Yonemura
et al. could show in a multivariate analysis that the com-
pleteness of cytoreduction is a highly significant factor for
the prediction of patient survival. Moreover, low PCI as
well as P1/P2 using the Japanese classification or stage I/
II using the Lyon classification indicating limited extent of
peritoneal tumor dissemination were associated with bet-
ter prognosis [46].
Cytoreductive surgery has already been shown to improve
survival of patients with stage III and IV ovarian cancer
previous to introduction of the combined treatment con-
cept with CRS and HIPEC [10]. Nevertheless, further
improvement of long-term survival is reported for CRS
and HIPEC in selected patients. In several studies the
median survival rates range from 28 to 46 months and 5-
year survival rates from 15 to 50% [26].
DMPM is a rare disease with relatively low incidence.
Thus, in the systemic review published by Yan et al. sur-
vival data of only seven studies including 12 to 100
patients are reported [47]. In these studies median sur-
vival ranges between 34 and 92 months and the 5-year
survival rates between 33% and 59%, respectively. All
studies showed a significant improvement of survival
compared to historical controls. Nevertheless, a prospec-
tive randomized controlled trial comparing the best avail-
able therapy – especially after introduction of
permetrexed for the systemic treatment of DMPM – with
or without CRS and HIPEC is still not available.
Quality of life after CRS and HIPEC
Despite relatively high morbidity rates and consecutive
initial impairment of quality of life (QoL) several studies
could show an improvement of QoL after CRS and HIPEC
in long-term survivors [48-52]. McQuellon et al. reported
an initial decrease of physical, functional and well-being
scores with an increase relative to baseline levels during
follow-up at 3, 6 and 12 months. One year after surgery
74% of the patients resumed > 50% of their normal activ-
ities [49]. In another publication McQuellon et al. con-
cluded that acceptable QoL, return of functional status
and reduced pain can be attained 3 to 6 months after CRS
and HIPEC. However, a significant number of patients
show depressive symptoms at the time of surgery (32%)
as well as one year after surgery (24%) [52]. Schmidt et al.
evaluated QoL after CRS and HIPEC in 67 patients with
peritoneal carcinomatosis using the EORTC QLQ-C30
questionnaire. The mean score for global health status of
long-term survivors was significantly decreased compared
to the control population (62.6 vs. 73.3) showing partic-
ularly an impairment of role and social functioning [48].World Journal of Surgical Oncology 2009, 7:5 http://www.wjso.com/content/7/1/5
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Tuttle et al. showed a return of QoL measurements to
baseline 4 months after surgery in a prospective analysis
of 35 patients. Eight and twelve months after CRS and
HIPEC QoL was significantly improved [51]. In conclu-
sion, the existing studies show that CRS and HIPEC can be
performed with acceptable postoperative QoL and even
may improve QoL in a selected part of long-term survi-
vors.
Conclusion
Cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy provide a promising therapeutic option for
highly selected patients with peritoneal carcinomatosis
arising from different malignancies such as colorectal can-
cer, gastric cancer, ovarian cancer or peritoneal mesotheli-
oma. Numerous studies with different levels of evidence
have shown that the integration of CRS and HIPEC in an
interdisciplinary treatment concept may improve the
oncological outcome compared to sole palliative systemic
chemotherapy. The completeness of cytoreduction plays a
pivotal role for long-term survival. Thus, consequent pre-
operative diagnostic workup and patient selection is
essential. The existing studies also show that the com-
bined treatment concept can be performed with low mor-
tality and acceptable morbidity in specialized centers. The
rate of complications is influenced by the extent of surgery
and the cytostatic agent used for intraperitoneal applica-
tion and its concentration. The quality of life is initially
impaired by surgery and postoperative complications.
Nevertheless, the functional status returns to baseline in
most patients during the first 4 moths after surgery. In
selected patients QoL may even be improved one year or
later after surgery.
However, for most tumor entities prospective randomized
controlled trials comparing best available therapy using
new therapeutic agents and combined systemic chemo-
therapy with and without CRS and HIPEC are still not
available. Such studies may provide higher levels of evi-
dence in the future and help to determine the significance
of CRS and HIPEC as an integrative part of an interdisci-
plinary cancer treatment strategy in selected patients with
peritoneal carcinomatosis.
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